<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387461</url>
  </required_header>
  <id_info>
    <org_study_id>CG2003C</org_study_id>
    <secondary_id>Mk3475 Keynote 935</secondary_id>
    <nct_id>NCT04387461</nct_id>
  </id_info>
  <brief_title>Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin</brief_title>
  <acronym>CORE-001</acronym>
  <official_title>A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CG Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CG Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the activity of intravesical administration of CG0070 and intravenous&#xD;
      administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular&#xD;
      invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease&#xD;
      with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An opened label trial designed to evaluate CG0070 and DDM in combination with Pembrolizumab&#xD;
      in patients with NMIBC who have failed prior BCG therapy.&#xD;
&#xD;
      The target population of 37 subjects with CIS with or without concomitant high-grade Ta or T1&#xD;
      papillary disease will be enrolled.&#xD;
&#xD;
      BCG failure is defined as persistent or recurrent disease within 12 months of completion of&#xD;
      adequate BCG therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate in patients</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events when CG0070 administered intravesically when combined with pembrolizumab.</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients with adverse events by grade as determined by NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (DoR)</measure>
    <time_frame>12 months</time_frame>
    <description>Median duration of response in patients with a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Median overall survival in months in patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Median duration of progression free survival of patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Non Muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.&#xD;
Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.&#xD;
Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CG0070</intervention_name>
    <description>Engineered Oncolytic Adenovirus</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab Injection</intervention_name>
    <description>Immune checkpoint inhibitor, Monoclonal antibody</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>n-dodecyl-B-D-maltoside</intervention_name>
    <description>Transduction-enhancing agent.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>DDM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1&#xD;
&#xD;
          -  Pathologically confirmed NMIBC with CIS (with or without Ta/T1 disease)&#xD;
&#xD;
          -  Unresponsive to prior BCG therapy (Lerner 2015) defined as persistent or recurrent CIS&#xD;
             alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the sub-&#xD;
             epithelial connective tissue) disease within 12 months of completion of adequate BCG&#xD;
             therapy. An assessment within 15 months can also qualify when no assessment was&#xD;
             performed within 12 months after completion of adequate BCG therapy.&#xD;
&#xD;
               -  Adequate BCG is defined as at least 5 treatments with induction BCG followed by&#xD;
                  at least 2 BCG treatments as reinduction or maintenance&#xD;
&#xD;
          -  Ineligible for radical cystectomy or refusal of radical cystectomy&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Immuno-deficient due to chronic steroid or other immunosuppressant use, HIV, or prior&#xD;
             organ transplant&#xD;
&#xD;
          -  Prior treatment with adenovirus-based cancer therapy&#xD;
&#xD;
          -  Prior therapy with or intolerant to prior checkpoint inhibitor therapy&#xD;
&#xD;
          -  Clinically significant or active cardiac disease&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Burke</last_name>
    <role>Principal Investigator</role>
    <affiliation>CG Oncology, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maira Ansari</last_name>
    <phone>(949) 346 -4040</phone>
    <email>maira.ansari@CGoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelica Craighead</last_name>
    <phone>415-640-2322</phone>
    <email>angelica.craighead@cgoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BCG Oncology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbi Mobley</last_name>
    </contact>
    <investigator>
      <last_name>Donald Lamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Padilla</last_name>
    </contact>
    <investigator>
      <last_name>Tyler Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Bereta</last_name>
    </contact>
    <investigator>
      <last_name>Edward Uchio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Department</last_name>
      <phone>424-212-4593</phone>
    </contact>
    <investigator>
      <last_name>Richard David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazmin Rodriguez</last_name>
    </contact>
    <investigator>
      <last_name>Roger Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jimmy Benning</last_name>
    </contact>
    <investigator>
      <last_name>Joshua Meeks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institution</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliya Lalji</last_name>
    </contact>
    <investigator>
      <last_name>Trinity Bivalacqua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Paxton</last_name>
    </contact>
    <investigator>
      <last_name>Rian Dickstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902-9823</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Kroeninger</last_name>
    </contact>
    <investigator>
      <last_name>Paras Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Chaisson</last_name>
    </contact>
    <investigator>
      <last_name>Gary Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicholas Carusone</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Jacob, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Jewell</last_name>
    </contact>
    <investigator>
      <last_name>Debasish Sundi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keystone Urology Specialists</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Stern</last_name>
    </contact>
    <investigator>
      <last_name>Paul Sieber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rutika Kokate</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Geynisman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spokane Urology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bardwell</last_name>
    </contact>
    <investigator>
      <last_name>Shane Pearce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mi Young Jung</last_name>
    </contact>
    <investigator>
      <last_name>Seung II Jung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seok Young Kim</last_name>
    </contact>
    <investigator>
      <last_name>Seok Ho Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Hee Kim</last_name>
    </contact>
    <investigator>
      <last_name>Ja Hyeon Ku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jung Park</last_name>
    </contact>
    <investigator>
      <last_name>Sung Hoo Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Sinchon-dong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Jin Jung</last_name>
    </contact>
    <investigator>
      <last_name>Jong Kil Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high-grade Ta papillary disease</keyword>
  <keyword>high-grade T1 papillary disease</keyword>
  <keyword>carcinoma in situ</keyword>
  <keyword>Bacillus-Calmette-Guerin Unresponsive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

